key: cord-0821971-dnb8wnyp authors: Moreira, Luiz Vinicius Leão; de Souza Luna, Luciano Kleber; Barbosa, Gabriela Rodrigues; Perosa, Ana Helena; Chavez, Ana Paula Cunha; Conte, Danielle Dias; Carvalho, Joseane Mayara Almeida; Bellei, Nancy title: Test on stool samples improves the diagnosis of hospitalized patients: detection of SARS-CoV-2 genomic and subgenomic RNA date: 2020-12-01 journal: J Infect DOI: 10.1016/j.jinf.2020.11.034 sha: 98cb38858ae37bd25bc54d655834a5ef17af99b9 doc_id: 821971 cord_uid: dnb8wnyp nan Dear Editor, As reported in this journal, SARS-CoV-2 has a prolonged detection in stool samples but its clinical significance is unclear (1) . Other studies have shown that the virus is detected longer in stool but its infectivity or replication status is not yet well established, although some association between the detection of SARS-CoV-2 subgenomic RNA (sgRNA) and virus isolation in cell culture has also been observed (2) (3) (4) (5) . On the other hand, virus detection in upper respiratory tract (URT) samples lasts in general up to the eighth-day post symptoms, with a decrease in detection beyond the fifth- The reactions were performed as described elsewhere (7). The threshold cycle (Ct) values were used as a semi-quantitative parameter, meaning that the higher the RNA sample concentration, the lower is the Ct value. The variation of Ct values for each sample between gRNA, their sgRNA counterparts, and between sgRNAs, were calculated as ΔCt. Viral RNA was detected in 23.0% (17/74) of the stool samples, with a mean Ct value of 27.4 ± 6.0 (mean ± SD). In those positive samples, the N and E sgRNAs were detected in 94.11% (16/17) and 58.82% (10/17), respectively. The ΔCt values were on average 7.22 ± 1.42 and 2.93 ± 1.83 higher for E and N sgRNAs, respectively (table 1), corresponding to a lower sensibility in an order of 2 and 1 Log10, in relation to the gRNA detection. The mean ΔCt value between E and N sgRNAs was 4.43±0,61. The number of days after the onset of symptoms in patients with SARS-CoV-2 detected in stool varied from 2 to 37 days (mean of 13.3 ± 11), with a mean hospitalization time of 24.7 ± 16.7 days. The presence of SARS-CoV-2 in stool samples could be related to the swallowing of respiratory secretions from the URT or residues of infected antigen-presenting immune cells (8) , or more probably due to virus replication in gastrointestinal epithelial cells (4) . However, the detection of viral RNA in stool was not related to gastrointestinal symptoms or COVID-19 severity (5, 9) . We were able to detect the SARS-CoV-2 sgRNA of E and N genes in positive stool samples. Interestingly, the authors who developed the protocol for the detection of E sgRNA did not report any detection in the stool of hospitalized patients (6) . When we compare the ΔCt between gRNA and their corresponding sgRNAs, for each sample, we observed a difference of 1 to 2 log10 of sensitivity, for mRNAs of N and E, respectively. Those differences could be explained by the fact that N sgRNA is the most abundantly expressed transcript during viral replication, followed by E sgRNA in an amount of approximately 1.5 Log10 lower transcripts (10) . We also roughly observed this difference between N and E sgRNAs detection with a ΔCt = 4.43 ± 0.61. Even though these findings, the detection of sgRNAs in clinical samples per se does not necessarily imply infectivity which is more related to days post symptoms and viral load (2, 3, 6) . However, the detection of more than one sgRNA could be used as markers of viral replication, although further studies are needed to confirm this hypothesis. In conclusion, viral detection in stool improves the diagnosis of COVID-19, especially in patients who are suspected of having infection but with negative results in UTR samples. None. SARS-CoV-2 detection, viral load and infectivity over the course of an infection Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants Virus Culture and Subgenomic RNA for Respiratory Specimens from Patients with Mild Coronavirus Disease. Emerg Infect Dis Evidence for Gastrointestinal Infection of SARS-CoV-2 The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients Virological assessment of hospitalized patients with COVID-2019 No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19 SARS-CoV-2 from faeces to wastewater treatment: What do we know? A review Fecal specimen diagnosis 2019 novel coronavirusinfected pneumonia The Architecture of SARS-CoV-2 Transcriptome